Innovative RAS Platform Virtual Incision's development of the MIRA robotic-assisted surgery system positions it as a cutting-edge provider in minimally invasive surgical technology, presenting opportunities for hospitals and surgical centers seeking to upgrade their operating rooms with advanced RAS capabilities.
Growing Market Presence With recent collaborations, strategic hires, and significant funding totaling over 87 million dollars, Virtual Incision is expanding its operational footprint and market reach, creating potential sales avenues with healthcare institutions looking to adopt emerging surgical technologies.
Recognition and Credibility Receiving the Governor's Bioscience Award and FDA authorization through the De Novo pathway enhances Virtual Incision’s reputation, making it more attractive to leading healthcare providers interested in partnering with trusted innovators in medical devices.
Product Commercialization Readiness With nearly 100 million dollars in funding and a focus on making operating rooms RAS-ready, Virtual Incision is approaching the commercial sales stage, offering opportunities for sales teams to target hospitals and surgical centers preparing to adopt robotic systems.
Patent Portfolio Advantage Holding over 200 patents and applications, Virtual Incision offers a proprietary edge in surgical robotics, which can be leveraged to build strong value propositions with healthcare providers seeking exclusive and innovative surgical solutions.